This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stanford Wessler, MD

JAMA. 1981;246(21):2484-2487.

Abstract
Recent multicenter clinical trials using platelet-suppressive agents for the secondary prevention of myocardial infarction have yielded inconclusive results, although some of the data suggest possible benefits. For transient ischemic attacks, after carotid artery surgery has been eliminated as an option, aspirin is the drug of choice for men; for women, and for men in whom aspirin fails, warfarin sodium should be considered. Warfarin is indicated after insertion of cardiac prosthetic disk valves, and if systemic emboli occur, dipyridamole should be added. Patients with atrial fibrillation should be treated prophylactically with coumarin agents, but only if underlying organic heart disease is demonstrable.

(JAMA 1981;246:2484-2487)

Author Affiliations
From the Department of Medicine, New York University School of Medicine.

Footnotes
Read in part before The Scientific Sessions, American Heart Association, Miami, Nov 18, 1980.

Reprint requests to The New York University School of Medicine, 550 First Ave, New York, NY 10016.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?